{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '3.3.2.', 'Risk Assessment for Tiotropium Bromide 18 mcg', 'Tiotropium is a marketed drug that contains tiotropium bromide (18 mcg). A similar', 'profile of undesirable effects as reported for anticholinergics (umeclidinium) may occur', 'with tiotropium bromide. The most common drug related adverse reactions are', 'pharmacologically predictable side effects for anti-cholinergic therapy, such as dry', 'mouth, blurred vision, dizziness, headache and cough. Please refer to the authorised', 'product label for further information on the risks of using Spiriva Handihaler. In this', 'study, tiotropium will be used in line with the recommendations provided in the product', 'label.', 'Tiotropium is an anticholinergic, therefore the risk mitigation strategy for UMEC', 'component of GSK2834425 will be applicable for tiotropium.', '3.3.3.', 'Benefit Assessment', 'GlaxoSmithKline is developing FF/UMEC/VI in a single inhaler, with the aim of', 'providing a new treatment option for the management of symptomatic COPD participants', 'at risk for exacerbations which will reduce the exacerbation frequency, allow for a', 'reduced burden of polypharmacy, convenience, and increase the potential for', 'improvement in lung function, HRQoL, and symptom control over established', 'dual/monotherapies.', 'Current risks have been identified for the FF/UMEC/VI (100/62.5/25 mcg) combination', 'based on the known pharmacology of the individual components, FF, UMEC, and VI,', 'alone or in combination. These include key risks of pneumonia and bone', 'disorders/fractures from ICS-containing combinations, and the risk of adverse', 'cardiovascular effects from LAMA and/or LABA-containing combinations.', 'In the US, the FF/VI combination is approved for the maintenance treatment of airflow', 'obstruction and for reduction of exacerbations in COPD. The UMEC/VI combination is', 'approved for maintenance treatment of airflow obstruction in COPD. UMEC is indicated', 'for the long-term, once-daily, maintenance treatment of airflow obstruction in', 'participants with COPD.', 'In the EU, the FF/VI combination is approved for the symptomatic treatment of adults', 'with COPD with an FEV <70 % predicted normal (post-bronchodilaotr) with an', 'exacerbation history despite regular bronchodilator therapy. The UMEC/VI combination', 'is approved as a maintenance bronchodilator to relieve symptoms in adult participants', 'with COPD. UMEC is approved as a maintenance bronchodilator treatment to relieve', 'symptoms in adult participants with COPD.', 'An appropriate safety monitoring strategy is being proposed for all risks associated with', 'the FF/UMEC/VI combination, including the key risks (Section 3.3.1).', 'Given the clinical experience with FF, UMEC, and VI, and that the associated risks with', 'these compounds are anticipated from their known pharmacology, the potential benefit of', 'a new therapy option in participants with moderate to severe COPD supports the further', 'development of the closed triple combination.', '35']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Tiotropium (18 mcg) is a marketed drug for the COPD indication, and has an established', 'benefit:risk profile. Tiotropium will be used in line with the recommendations provided', 'in the product label.', '3.3.4.', 'Overall Benefit:Risk Conclusion', 'Taking into account the measures taken to minimize risk to participants participating in', 'this study, the potential risks identified in association with FF/UMEC/VI and tiotropium', 'are justified by the anticipated benefits from active treatments that may be afforded to', 'participants with COPD.', '36']\n\n###\n\n", "completion": "END"}